Stephen W. LaFon

1.6k total citations
26 papers, 1.2k citations indexed

About

Stephen W. LaFon is a scholar working on Epidemiology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Stephen W. LaFon has authored 26 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 12 papers in Molecular Biology and 11 papers in Infectious Diseases. Recurrent topics in Stephen W. LaFon's work include Biochemical and Molecular Research (10 papers), HIV/AIDS drug development and treatment (10 papers) and Trypanosoma species research and implications (8 papers). Stephen W. LaFon is often cited by papers focused on Biochemical and Molecular Research (10 papers), HIV/AIDS drug development and treatment (10 papers) and Trypanosoma species research and implications (8 papers). Stephen W. LaFon collaborates with scholars based in United States, United Kingdom and Sweden. Stephen W. LaFon's co-authors include Donald J. Nelson, J. Joseph Marr, Randolph L. Berens, Henry Masur, Judith Falloon, Danny J. Lancaster, Thomas A. Krenitsky, Gertrude B. Elion, Richard L. Miller and Wayne H. Miller and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Clinical Infectious Diseases.

In The Last Decade

Stephen W. LaFon

26 papers receiving 1.1k citations

Peers

Countries citing papers authored by Stephen W. LaFon

Since Specialization

Citations

This map shows the geographic impact of Stephen W. LaFon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen W. LaFon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen W. LaFon more than expected).

Fields of papers citing papers by Stephen W. LaFon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen W. LaFon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen W. LaFon. The network helps show where Stephen W. LaFon may publish in the future.

Co-authorship network of co-authors of Stephen W. LaFon

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen W. LaFon. A scholar is included among the top collaborators of Stephen W. LaFon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen W. LaFon. Stephen W. LaFon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combination Therapy with Amprenavir, Abacavir, and Efavirenz in Human Immunodeficiency Virus (HIV)-Infected Patients Failing a Protease-Inhibitor Regimen: Pharmacokinetic Drug Interactions and Antiviral Activity 2000 ·Clinical Infectious Diseases ·Judith Falloon, Stephen C. Piscitelli, (unknown), Brian M. Sadler, Hiroaki Mitsuya, Mark F. Kavlick, Kazuhisa Yoshimura, M. Brooke Rogers, Stephen W. LaFon, Douglas J. Manion, H. Clifford Lane, Henry Masur	65
2	Use of Drug Effect Interaction Modeling with Monte Carlo Simulation To Examine the Impact of Dosing Interval on the Projected Antiviral Activity of the Combination of Abacavir and Amprenavir 2000 ·Antimicrobial Agents and Chemotherapy ·George L. Drusano, David Z. D’Argenio, Sandra L. Preston, Carlo Barone, (unknown), Stephen W. LaFon, M. Brooke Rogers, William Prince, Alan Bye, John A. Bilello	38
3	Atovaquone Suspension in HIV‐Infected Volunteers: Pharmacokinetics, Pharmacodynamics, and TMP‐SMX Interaction Study 1999 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Judith Falloon, (unknown), Stephen C. Piscitelli, (unknown), Stephen W. LaFon, Brian M. Sadler, Robert Walker, Joseph A. Kovacs, Michael A. Polis, Richard T. Davey, H. Clifford Lane, Henry Masur	33
4	Safety and Pharmacokinetics of Abacavir (1592U89) following Oral Administration of Escalating Single Doses in Human Immunodeficiency Virus Type 1-Infected Adults 1999 ·Antimicrobial Agents and Chemotherapy ·Princy Kumar, Donna E. Sweet, James A. McDowell, William T. Symonds, Yu Lou, Seth Hetherington, Stephen W. LaFon	54
5	Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults 1998 ·AIDS ·Michael S. Saag, Anders Sönnerborg, Ramón A. Torres, Danny J. Lancaster, Brian Gazzard, Robert T. Schooley, Carmen Romero, Dennis Kelleher, William Spreen, Stephen W. LaFon	70
6	Effects of Aerosolized Synthetic Surfactant, Atovaquone, and the Combination of These on Murine Pneumocystis carinii Pneumonia 1998 ·The Journal of Infectious Diseases ·Walter T. Hughes, Elaine M. Sillos, Stephen W. LaFon, Michael J. Rogers, Joseph L. Woolley, Christine Davis, Scott D. Studenberg, Edward N. Pattishall, (unknown), Graham M. Snyder, (unknown)	12
7	Adverse Events Associated with Trimethoprim-Sulfamethoxazole and Atovaquone during the Treatment of AIDS-Related Pneumocystis carinii Pneumonia 1995 ·The Journal of Infectious Diseases ·Walter T. Hughes, Stephen W. LaFon, John D. Scott, Henry Masur	64
8	Clinical Experience with Atovaquone on a Treatment Investigational New Drug Protocol for Pneumocystis carinii Pneumonia 1995 ·Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·Alice White, Stephen W. LaFon, Michael M. Rogers, Elizabeth Andrews, Nathaniel Brown	6
9	Comparison of Atovaquone (566C80) with Trimethoprim-Sulfamethoxazole to Treat Pneumocystis carinii Pneumonia in Patients with AIDS 1993 ·New England Journal of Medicine ·Walter Hughes, Gifford Leoung, Françoise Kramer, Samuel A. Bozzette, Sharon Safrin, (unknown), Nathan Clumeck, Henry Masur, Danny J. Lancaster, Charles K. Chan, James P. Lavelle, (unknown), Judith Falloon, Judith Feinberg, Stephen W. LaFon, Michael J. Rogers, Fred R. Sattler	204
10	Antiprotozoal activity of 3′-deoxyinosine 1991 ·Biochemical Pharmacology ·Allan R. Moorman, Stephen W. LaFon, Donald J. Nelson, (unknown), J. Joseph Marr, Randolph L. Berens	9
11	A Preliminary Evaluation of 566C80 for the Treatment of Pneumocystis Pneumonia in Patients with the Acquired Immunodeficiency Syndrome 1991 ·New England Journal of Medicine ·Judith Falloon, Joseph A. Kovacs, Walter Hughes, (unknown), Michael A. Polis, Richard T. Davey, Michael J. Rogers, Stephen W. LaFon, Irwin M. Feuerstein, Danny J. Lancaster, (unknown), Carmelita U. Tuazon, Michael N. Dohn, (unknown), H. Clifford Lane, Henry Masur	61
12	Prophylactically Administered Retrovir(R) in Health Care Workers Potentially Exposed to the Human Immunodeficiency Virus 1988 ·The Journal of Infectious Diseases ·Stephen W. LaFon, Sandra Nusinoff Lehrman, David W. Barry	14
13	Antigiardial activity of guanine arabinoside mechanism studies 1987 ·Biochemical Pharmacology ·Richard L. Miller, Donald J. Nelson, Stephen W. LaFon, Wayne H. Miller, Thomas A. Krenitsky	11
14	Inosine analogs. Their metabolism in mouse L cells and in Leishmania donovani. 1985 ·Journal of Biological Chemistry ·Stephen W. LaFon, Donald J. Nelson, Randolph L. Berens, J. Joseph Marr	45
15	Purine metabolism in the intact sporozoites and merozoites of Eimeria tenella 1985 ·Molecular and Biochemical Parasitology ·Stephen W. LaFon, David J. Nelson	11
16	Antileishmanial action of 4-thiopyrazolo (3,4-d)pyrimidine and its ribonucleoside 1982 ·Biochemical Pharmacology ·J. Joseph Marr, Randolph L. Berens, Donald J. Nelson, Thomas A. Krenitsky, Thomas Spector, Stephen W. LaFon, Gertrude B. Elion	36
17	Purine and pyrimidine salvage pathways in Leishmania donovani 1982 ·Biochemical Pharmacology ·Stephen W. LaFon, Donald J. Nelson, Randolph L. Berens, J. Joseph Marr	55
18	The metabolism of formycin B in Leishmaniadonovani 1982 ·Biochemical and Biophysical Research Communications ·Donald J. Nelson, Stephen W. LaFon, Thomas Jones, Thomas Spector, Randolph L. Berens, J. Joseph Marr	39
19	Purine metabolism in Trypanosoma cruzi 1981 ·Molecular and Biochemical Parasitology ·Randolph L. Berens, J. Joseph Marr, Stephen W. LaFon, Donald J. Nelson	69
20	Comparative Metabolism of a New Antileishmanial Agent, Allopurinol Riboside, in the Parasite and the Host Cell 1980 ·Advances in experimental medicine and biology ·Donald J. Nelson, Stephen W. LaFon, Gertrude B. Elion, J. Joseph Marr, Randolph L. Berens	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact